Bizily Scott 4
4 · 4D Molecular Therapeutics, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Bizily Scott
Chief Legal Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-11-17−1,635→ 75,230 totalExercise: $4.14Exp: 2035-03-05→ Common Stock (1,635 underlying) - Sale
Common Stock
2025-11-17$10.59/sh−1,635$17,315→ 3,594 total - Exercise/Conversion
Common Stock
2025-11-17$4.14/sh+1,635$6,769→ 5,229 total
Footnotes (2)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
- [F2]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.